Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 8/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.54 |
| ▸ | PAK4 | O96013 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | RET | P07949 | 3/20 | 0.54 |
| ▸ | MET | P08581 | 3/20 | 0.54 |
| ▸ | PIM1 | P11309 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | PRKACA | P17612 | 3/20 | 0.54 |
| ▸ | FLT1 | P17948 | 3/20 | 0.54 |
| ▸ | LTK | P29376 | 3/20 | 0.54 |
| ▸ | GRK5 | P34947 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.54 |
| ▸ | CLK2 | P49760 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006751 | 0.80 | JAK2 (1.00) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL13765436 | 0.79 | JAK2 (0.72) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL171455 | 0.78 | JAK2 (0.61) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL27753707 | 0.77 | JAK2 (0.70) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL15661177 | 0.77 | JAK2 (0.70) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL4582353 | 0.77 | JAK2 (0.70) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL4582349 | 0.77 | JAK2 (0.70) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL31187292 | 0.76 | JAK2 (0.63) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL22930855 | 0.76 | JAK2 (0.58) | JAK2IKBKBCHUKJAK3DAPK3 | |
| SCHEMBL13695624 | 0.75 | JAK2 (0.61) | JAK2IKBKBCHUKJAK3DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-23 | — | — | US | disclosed |
| US-8741912-B2 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741912-B2 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-12-13 | — | — | US | disclosed |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-12-13 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | JAK2 3/4885IKBKB 283/4885CHUK 62/4885 |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | JAK2 3/4885IKBKB 283/4885CHUK 62/4885 |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | JAK2 3/4885IKBKB 283/4885CHUK 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.